ProMIS Neurosciences Antibodies Inhibit Accumulation of Alzheimer’s-linked Protein, Study Shows

ProMIS Neurosciences Antibodies Inhibit Accumulation of Alzheimer’s-linked Protein, Study Shows
Antibodies that ProMIS Neurosciences created to target molecules associated with Alzheimer’s inhibit the accumulation of the amyloid beta protein that is a hallmark of the disease. The company's researchers used two computer algorithms, ProMI and Collective Coordinates, to predict amyloid beta misfolding and five disease-specific targets for antibodies, according to a presentation at a conference in Vienna. Misfolding leads to faulty versions of the protein  accumulating in the brain, which scientists believe is a key cause of Alzheimer's. Ebrima Gibbs of ProMIS presented the study's findings in a poster session at the 13th International Conference on Alzheimer's and Parkinson's diseases. The session was titled “Rational Generation Of Oligomer-Specific Antibodies Through Computational Identification Of Conformational Epitopes." After the researchers identified the antibody targets, they created the antibodies to use against them, Gibbs said. Administering the antibodies to neurons in a laboratory led to amyloid beta proteins clumping together. This aggregating inhibited its accumulation, promoting neuron protection and survival, the team said. The antibodies prompted amyloid beta to clump together in samples of brain tissue and cerebrospinal fluid from Alzheimer’s patients as well. The antibodies did not react against single units of amyloid beta, which are known as monomers, or in amyloid beta
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *